Pharmacoeconomic evaluation of genotype-guided dabigatran etexilate dosing in patients with atrial fibrillation and chronic kidney disease

Pharmacogenetic testing (PGT) is one of the promising personalized approaches to prescribing drugs in clinical practice. The PGT’s feasibility plays an important role in the oral anticoagulants (DOACs) administration, especially in the event of adverse reactions -hemorrhagic and thrombotic complications. According to the results of our study, personalized pharmacotherapy of dabigatran etexilate 110 and 150 mg reduced the frequency of bleeding (17,79 vs 18,10) and slightly exceeded the cost (cost difference was 216,55 rubles) compared with standard therapy in patients with atrial fibrillation in combination with chronic kidney disease. The PGT application can be used to improve the safety of DOAC pharmacotherapy. In the future, it is possible to decrease the costs of a medical organizations by reducing the cost of genetic tests.

rs2244613, atrial fibrillation, pharmacoeconomics, dabigatran etexilate, rs2244613, hemorrhagic events